Abstract
Glutathione reductase was purified 34806-fold with a final yield of 85 % from the bovine kidney cortex. Some molecular and kinetic properties of purified enzyme are investigated. Product inhibition studies showed that the enzyme obeys ‘branched’ mechanism: KmNADPH 18 ± 3 μM and KmGSSG 65 ± 5 μM were determined.
Keywords: Glutathione reductase, purification, kinetics, branched mechanism
Protein & Peptide Letters
Title: Purification and Kinetics of Bovine Kidney Cortex Glutathione Reductase
Volume: 17 Issue: 5
Author(s): Berivan Tandogan and N. Nuray Ulusu
Affiliation:
Keywords: Glutathione reductase, purification, kinetics, branched mechanism
Abstract: Glutathione reductase was purified 34806-fold with a final yield of 85 % from the bovine kidney cortex. Some molecular and kinetic properties of purified enzyme are investigated. Product inhibition studies showed that the enzyme obeys ‘branched’ mechanism: KmNADPH 18 ± 3 μM and KmGSSG 65 ± 5 μM were determined.
Export Options
About this article
Cite this article as:
Tandogan Berivan and Ulusu N. Nuray, Purification and Kinetics of Bovine Kidney Cortex Glutathione Reductase, Protein & Peptide Letters 2010; 17 (5) . https://dx.doi.org/10.2174/092986610791112684
DOI https://dx.doi.org/10.2174/092986610791112684 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Renal and Hepatic Transporter Expression in Type 2 Diabetic Rats
Drug Metabolism Letters Class IV Antiarrhythmic Agents: New Compounds Using an Old Strategy
Current Pharmaceutical Design Is Hyperhomocyst(e)inemia A Humoral Predictor of Coronary Heart Disease?
Current Pharmaceutical Design Pregnancy, Programming and Preeclampsia: Gap Junctions at the Nexus of Pregnancy-induced Adaptation of Endothelial Function and Endothelial Adaptive Failure in PE
Current Vascular Pharmacology Recent Developments in the Search for Biomarkers for the Diagnosis and Monitoring of Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Relationship between Proinflammatory Cytokines/Chemokines and Adipokines in Serum of Young Adults with Obesity
Endocrine, Metabolic & Immune Disorders - Drug Targets Inhibition of RET Activated Pathways: Novel Strategies for Therapeutic Intervention in Human Cancers
Current Pharmaceutical Design Recent Developments in Pharmacologic Prophylaxis of Atrial Fibrillation in Patients Undergoing Surgical Revascularization
Cardiovascular & Hematological Agents in Medicinal Chemistry Lipoproteins, Stroke and Statins
Current Vascular Pharmacology Localisation of Endothelin-1 and its Receptors in Vascular Tissue as Seen at the Electron Microscopic Level
Current Vascular Pharmacology Latest Results for Anti-Angiogenic Drugs in Cancer Treatment
Current Pharmaceutical Design Low-Dose Aspirin-Associated Upper and Mid Gastrointestinal Tract Damage and Gene Polymorphism
Current Pharmaceutical Design Foreword
Current Nutrition & Food Science Telemonitoring in the Management of High Blood Pressure
Current Pharmaceutical Design Clinical and Pre-clinical Applications of the Transcendental Meditation Program® in the Prevention and Treatment of Essential Hypertension and Cardiovascular Disease in Youth and Adults
Current Hypertension Reviews CDK9: Therapeutic Perspective in HCC Therapy
Current Cancer Drug Targets Mediterranean Diet and Risk of Dementia
Current Alzheimer Research Pathophysiological Role of Proteasome-Dependent Proteolytic Pathway in Endothelin-1-Related Cardiovascular Diseases
Current Vascular Pharmacology Vasopressin Secretion Control: Central Neural Pathways, Neurotransmitters and Effects of Drugs
Current Pharmaceutical Design Fused 1,4-Dihydropyridines as Potential Calcium Modulatory Compounds
Mini-Reviews in Medicinal Chemistry